Appelbaum, FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357(15):1472–5. Epub 2007/10/12. doi: 357/15/1472 [pii]10.1056/NEJMp078166. PubMed PMID: 17928594.CrossRefGoogle ScholarPubMed

Lazarus, HM, Phillips, GL, Herzig, RH, Hurd, DD, Wolff, SN, Herzig, GP. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol. 2008;26(14):2240–3. doi: 10.1200/JCO.2007.14.7827. PubMed PMID: 18467711.CrossRefGoogle ScholarPubMed

Sorror, ML, Maris, MB, Storb, R, Baron, F, Sandmaier, BM, Maloney, DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9. PubMed PMID: 15994282.CrossRefGoogle ScholarPubMed

McSweeney, PA, Niederwieser, D, Shizuru, JA, Sandmaier, BM, Molina, AJ, Maloney, DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–400. PubMed PMID: 11369628.CrossRefGoogle ScholarPubMed

Abidi, MH, Agarwal, R, Tageja, N, Ayash, L, Deol, A, Al-Kadhimi, Z, et al. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant. 2013;19(1):56–61. doi: 10.1016/j.bbmt.2012.08.003. PubMed PMID: 22892551; PubMed Central PMCID: PMC3786738.CrossRefGoogle ScholarPubMed

Vose, JM, Bierman, PJ, Loberiza, FR, Enke, C, Hankins, J, Bociek, RG, et al. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2013;19(1):123–8. doi: 10.1016/j.bbmt.2012.08.013. PubMed PMID: 22940055.CrossRefGoogle ScholarPubMed

Brenner, MK, Rill, DR, Holladay, MS, Heslop, HE, Moen, RC, Buschle, M, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993;342(8880):1134–7. PubMed PMID: 7901474.CrossRefGoogle ScholarPubMed

Arcaini, L, Montanari, F, Alessandrino, EP, Tucci, A, Brusamolino, E, Gargantini, L, et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol. 2008;19(7):1331–5. doi: 10.1093/annonc/mdn044. PubMed PMID: 18344536.CrossRefGoogle ScholarPubMed

Philip, T, Guglielmi, C, Hagenbeek, A, Somers, R, Van der Lelie, H, Bron, D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. New Engl J Med. 1995;333(23):1540–5. doi: 10.1056/NEJM199512073332305. PubMed PMID: 7477169.CrossRefGoogle ScholarPubMed

Weaver, CH, Appelbaum, FR, Petersen, FB, Clift, R, Singer, J, Press, O, et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol. 1993;11(7):1329–35. PubMed PMID: 8315430.CrossRefGoogle ScholarPubMed

Chen, YB, Lane, AA, Logan, B, Zhu, X, Akpek, G, Aljurf, M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015. doi: 10.1016/j.bbmt.2015.02.005. PubMed PMID: 25687795.CrossRefGoogle Scholar

Kalaycio, M, Rybicki, L, Pohlman, B, Sobecks, R, Andresen, S, Kuczkowski, E, et al. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol. 2006;24(22):3604–10. doi: 10.1200/JCO.2006.06.0673. PubMed PMID: 16877727.CrossRefGoogle ScholarPubMed

Shaw, PJ, Nath, CE, Lazarus, HM. Not too little, not too much-just right! (Better ways to give high dose melphalan). Bone Marrow Transplant. 2014. doi: 10.1038/bmt.2014.186. PubMed PMID: 25133893.CrossRefGoogle Scholar

Moreau, P, Facon, T, Attal, M, Hulin, C, Michallet, M, Maloisel, F, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99(3):731–5. PubMed PMID: 11806971.CrossRefGoogle Scholar

Moreau, P, Attal, M, Harousseau, JL. New developments in conditioning regimens before auto-HCT in multiple myeloma. Bone Marrow Transplant. 2011;46(7):911–5. doi: 10.1038/bmt.2011.20. PubMed PMID: 21358678.CrossRefGoogle Scholar

Atkins, HL, Muraro, PA, van Laar, JM, Pavletic, SZ. Autologous hematopoietic stem cell transplantation for autoimmune disease – is it now ready for prime time? Biol Blood Marrow Transplant. 2012;18(1 Suppl):S177–83. doi: 10.1016/j.bbmt.2011.11.020. PubMed PMID: 22226104.CrossRefGoogle ScholarPubMed

Baron, F, Labopin, M, Niederwieser, D, Vigouroux, S, Cornelissen, JJ, Malm, C, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26(12):2462–8. doi: 10.1038/leu.2012.135. PubMed PMID: 22699419.CrossRefGoogle ScholarPubMed

Craddock, C, Nagra, S, Peniket, A, Brookes, C, Buckley, L, Nikolousis, E, et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2010;95(6):989–95. Epub 2009/12/03. doi: 10.3324/haematol.2009.013920. PubMed PMID: 19951968; PubMed Central PMCID: PMC2878799.CrossRefGoogle ScholarPubMed

Bacigalupo, A, Ballen, K, Rizzo, D, Giralt, S, Lazarus, H, Ho, V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–33. doi: 10.1016/j.bbmt.2009.07.004. PubMed PMID: 19896087; PubMed Central PMCID: PMC2861656.CrossRefGoogle ScholarPubMed

Deeg, HJ, Sandmaier, BM. Who is fit for allogeneic transplantation? Blood. 2010;116(23):4762–70. doi: 10.1182/blood-2010-07-259358. PubMed PMID: 20702782; PubMed Central PMCID: PMC3253743.CrossRefGoogle ScholarPubMed

Sorror, ML, Giralt, S, Sandmaier, BM, De Lima, M, Shahjahan, M, Maloney, DG, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4606–13. PubMed PMID: 17873123.CrossRefGoogle ScholarPubMed

Copelan, EA, Hamilton, BK, Avalos, B, Ahn, KW, Bolwell, BJ, Zhu, X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122(24):3863–70. doi: 10.1182/blood-2013-07-514448. PubMed PMID: 24065243; PubMed Central PMCID: PMC3854108.CrossRefGoogle ScholarPubMed

Nagler, A, Rocha, V, Labopin, M, Unal, A, Ben Othman, T, Campos, A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen – a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31(28):3549–56. doi: 10.1200/JCO.2013.48.8114. PubMed PMID: 23980086.CrossRefGoogle ScholarPubMed

Socie, G, Clift, RA, Blaise, D, Devergie, A, Ringden, O, Martin, PJ, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98(13):3569–74. PubMed PMID: 11739158.CrossRefGoogle ScholarPubMed

Andersson, BS, de Lima, M, Thall, PF, Wang, X, Couriel, D, Korbling, M, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008;14(6):672–84. doi: 10.1016/j.bbmt.2008.03.009. PubMed PMID: 18489993.CrossRefGoogle ScholarPubMed

Lee, JH, Joo, YD, Kim, H, Ryoo, HM, Kim, MK, Lee, GW, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31(6):701–9. doi: 10.1200/JCO.2011.40.2362. PubMed PMID: 23129746.Google ScholarPubMed

Ram, R, Storb, R, Sandmaier, BM, Maloney, DG, Woolfrey, A, Flowers, ME, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96(8):1113–20. Epub 2011/04/22. doi: 10.3324/haematol.2011.040261. PubMed PMID: 21508120; PubMed Central PMCID: PMC3148904.CrossRefGoogle ScholarPubMed

Slavin, S, Nagler, A, Naparstek, E, Kapelushnik, Y, Aker, M, Cividalli, G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–63. PubMed PMID: 9446633.CrossRefGoogle ScholarPubMed

Giralt, S, Estey, E, Albitar, M, van Besien, K, Rondon, G, Anderlini, P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531–6. PubMed PMID: 9192777.CrossRefGoogle ScholarPubMed

Nemecek, ER, Guthrie, KA, Sorror, ML, Wood, BL, Doney, KC, Hilger, RA, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(3):341–50. doi: 10.1016/j.bbmt.2010.05.007. PubMed PMID: 20685259; PubMed Central PMCID: PMC2974965.CrossRefGoogle ScholarPubMed

Chevallier, P, Labopin, M, Buchholz, S, Ganser, A, Ciceri, F, Lioure, B, et al. Clofarabine-containing conditioning regimen for allo-HCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol. 2012;89(3):214–9. doi: 10.1111/j.1600-0609.2012.01822.x. PubMed PMID: 22702414.CrossRefGoogle Scholar

Childs, R, Chernoff, A, Contentin, N, Bahceci, E, Schrump, D, Leitman, S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. New Engl J Med. 2000;343(11):750–8. doi: 10.1056/NEJM200009143431101. PubMed PMID: 10984562.CrossRefGoogle ScholarPubMed

Childs, R, Clave, E, Contentin, N, Jayasekera, D, Hensel, N, Leitman, S, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94(9):3234–41. PubMed PMID: 10556212.CrossRefGoogle ScholarPubMed

Kottaridis, PD, Milligan, DW, Chopra, R, Chakraverty, RK, Chakrabarti, S, Robinson, S, et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy. 2001;3(3):197–201. PubMed PMID: 12171726.CrossRefGoogle ScholarPubMed

Soiffer, RJ, Lerademacher, J, Ho, V, Kan, F, Artz, A, Champlin, RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963–70. doi: 10.1182/blood-2011-01-332007. PubMed PMID: 21464372; PubMed Central PMCID: PMC3128486.CrossRefGoogle ScholarPubMed

Lush, RJ, Haynes, AP, Byrne, J, Cull, GM, Carter, GI, Pagliuca, A, et al. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy. 2001;3(3):203–10. Epub 2002/08/13. doi: 10.1080/146532401753174034. PubMed PMID: 12171727.CrossRefGoogle ScholarPubMed

Schmid, C, Schleuning, M, Ledderose, G, Tischer, J, Kolb, HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675–87. PubMed PMID: 16110027.CrossRefGoogle ScholarPubMed

Schmid, C, Schleuning, M, Schwerdtfeger, R, Hertenstein, B, Mischak-Weissinger, E, Bunjes, D, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108(3):1092–9. PubMed PMID: 16551971.CrossRefGoogle ScholarPubMed

Kohrt, HE, Turnbull, BB, Heydari, K, Shizuru, JA, Laport, GG, Miklos, DB, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114(5):1099–109. doi: 10.1182/blood-2009-03-211441. PubMed PMID: 19423725; PubMed Central PMCID: PMC2721787.CrossRefGoogle ScholarPubMed

Benjamin, J, Chhabra, S, Kohrt, HE, Lavori, P, Laport, GG, Arai, S, et al. Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biol Blood Marrow Transplant. 2014;20(6):837–43. doi: 10.1016/j.bbmt.2014.02.023. PubMed PMID: 24607552.CrossRefGoogle ScholarPubMed

Russell, NH, Kjeldsen, L, Craddock, C, Pagliuca, A, Yin, JA, Clark, RE, et al. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Leukemia. 2014. doi: 10.1038/leu.2014.319. PubMed PMID: 25376374.CrossRefGoogle Scholar

Blaise, D, Tabrizi, R, Boher, JM, Le Corroller-Soriano, AG, Bay, JO, Fegueux, N, et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer. 2013;119(3):602–11. doi: 10.1002/cncr.27786. PubMed PMID: 22893313.CrossRefGoogle ScholarPubMed

Pagel, JM, Gooley, TA, Rajendran, J, Fisher, DR, Wilson, WA, Sandmaier, BM, et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2009;114(27):5444–53. doi: 10.1182/blood-2009-03-213298. PubMed PMID: 19786617; PubMed Central PMCID: PMC2798861.CrossRefGoogle ScholarPubMed

Chen, YB, Li, S, Lane, AA, Connolly, C, Del Rio, C, Valles, B, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(12):2042–8. doi: 10.1016/j.bbmt.2014.09.007. PubMed PMID: 25239228; PubMed Central PMCID: PMC4253683.CrossRefGoogle ScholarPubMed

Goodyear, OC, Dennis, M, Jilani, NY, Loke, J, Siddique, S, Ryan, G, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361–9. Epub 2012/01/12. doi: 10.1182/blood-2011-09-377044. PubMed PMID: 22234690.CrossRefGoogle ScholarPubMed

Baron, F, Labopin, M, Blaise, D, Lopez-Corral, L, Vigouroux, S, Craddock, C, et al. Impact of in-vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-HCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(3):389–96. doi: 10.1038/bmt.2013.204. PubMed PMID: 24419525.CrossRefGoogle Scholar

Peggs, KS, Sureda, A, Qian, W, Caballero, D, Hunter, A, Urbano-Ispizua, A, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139(1):70–80. doi: 10.1111/j.1365–2141.2007.06759.x. PubMed PMID: 17854309.CrossRefGoogle ScholarPubMed

Negrin, RS. Role of regulatory T cell populations in controlling graft vs host disease. Best Pract Res Clin Haematol. 2011;24(3):453–7. doi: 10.1016/j.beha.2011.05.006. PubMed PMID: 21925098; PubMed Central PMCID: PMC3176418.CrossRefGoogle ScholarPubMed